Treatment patterns, survival, and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
CONCLUSIONS: ET was the most common first-line treatment for study patients, but its use decreased gradually in the subsequent lines. The heterogeneity in the treatment selection highlights a lack of consensus for the management of HR+/HER2- MBC in routine practice.
PMID: 31060392 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Endocrine Therapy | Health Management | HER2 | Medicare | Neurology | Research | Study